

FIG 1. Quenching of QS21 haemolytic activity with cholesterol




FIG. 2. Hydrolysis of QS21 in alkaline aqueous medium




FIG 3. Anti-gp120 CTL activity generated by QS21 as adjuvant




FIG 4. Anti-gp120 CTL activity generated by QS21 and cholesterol containing liposome as adjuvant







FIG 5. Anti-gD antibodies in AGM




**FIG 6.** Antigen specific proliferation was measured by stimulation in vitro with gD coupled to microbeads, and expressed as CPM of 3H-TdR incorporated.





**FIG 7.** IL-2 production of cells after gD vaccination and restimulation in vitro.

**FIG 8.** Interferon gamma production of cells after gD vaccination and restimulation in vitro



**FIG 9.** RSV neutralisation titres and anti FG ELISA titres after vaccination



**FIG 10.** Comparison of QS21-SUV containing formulations with Alum formulation  
Kinetics of the anti-HBs response (post I/II)








Figure 10 (continued)



**FIG 11. Comparison of QS21-SUV containing formulations with Alum formulation Isotypic profile (post II) anti-HBs response**



	% IgG1	% IgG2a	% IgG2b
S,L* /Alum	93	3	3
S,L* /alum/MPL/QS21-SUV	44	46	10
S,L* /alum / QS21-SUV	44	47	9
S,L* /MPL /QS21-SUV	27	55	18